BCR/ABL, Tyrosine Kinase Inhibitor Resistance, Kinase Domain Mutation Screen
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Evaluating patients with chronic myeloid leukemia and Philadelphia chromosome positive B-cell acute lymphoblastic leukemia receiving tyrosine kinase inhibitor (TKI), therapy, who are apparently failing treatment
This is the preferred initial test to identify the presence of acquired BCR-ABL mutations associated with TKI-resistance.
Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.
If BCR/ABL fusion type (p210, p190, p185 or p230) are not provided, BADX / BCR/ABL, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Qualitative, Diagnostic Assay will be performed at an additional charge.
Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) with Fluorescent-Bead Array Analysis Allele-Specific Primer Extension (ASPE) and Detection by Luminex Bead Array
(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name